03:08 AM EDT, 10/30/2026 (MT Newswires) -- Sanofi (SAN.PA) logged 3.02 billion euros in net income attributable to equity holders for the third quarter, compared with 2.80 billion euros a year ago. Basic EPS moved to 2.52 euros from 2.30 euros year over year, a Friday filing showed. For the three months ended Sept. 30, net sales were 14.44 billion euros versus 12.43 billion euros previously, the French pharmaceutical company added. Looking ahead, the company raised its full-year 2026 sales outlook to a low-teens percentage growth at constant exchange rates, compared with 10% growth previously. Business EPS is expected to grow by a mid-teens percentage at constant exchange rates, compared with the previous guidance of slightly faster growth than sales.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.